FORM 12B-25 NOTIFICATION OF LATE FILING
SEC FILE NUMBER
CUSIP NUMBER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Check One): x Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR
For Period Ended: December 31, 1997
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-A
Transition Report on Form N-SAR
For the Transition Period Ended:
Read Instruction (on back page) Before Preparing Form, Please Print or Type.
Nothing in this form shall be construed to imply that the Commissions have
verified any information contained
herein.
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification
relates:
PART I REGISTRATION INFORMATION (Official Text)
Full Name of Registrant: IGENE Biotechnology, Inc.
Former Name if Applicable:
Address of Principal Executive
Office (Street and Number): 9110 Red Branch Road
City, State and Zip Code: Columbia, Maryland 21045-2024
PART II RULES 1b-25(b) AND (c) (Official Text)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant
to Rule 12b-25(b), the following should be completed. (Check box if
appropriate) x
(a) The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F, 11-K, form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report of transition report on Form 10-Q,
or portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and (c) The accountants statement or
other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III NARRATIVE (Official Text)
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period. (Attach Extra Sheets if Needed)
PART IV OTHER INFORMATION (Official Text)
(1) Name and telephone number of person to contact in regard to this
notification
Stephen F. Hiu
410-997-2599
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 of Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
YES
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statement to be included in the subject report or portion
thereof?
NO
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Name of Registrant as Specified in Charter: IGENE Biotechnology, Inc. has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: March 25, 1998
By: /s/ Stephen F. Hiu, Ph.D., President
INSTRUCTIONS:
The form may be signed by an executive officer of the registrant or by any
other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representatives authority
to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements of omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
GENERAL INSTRUCTIONS (Official Text)
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules
and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information contained in or
filed with the form will be made a matter of public record in the Commission
files.
3. A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of
the registrant is registered.
4. Amendment to the notification must also be filed on Form 12b-25 but need
not restate information that has been correctly furnished. The form shall be
clearly identified as an amendment notification.
5. Electronic Filers. This form shall not be used by electronic filers
unable to timely file a report solely due to electronic difficulties. Filers
unable to submit a report within the time period prescribed due to
difficulties in electronic filing should comply with either Rule 201 or
Rule 202 of Regulation S-T (232.201 or 232.202 of this chapter) or apply for
an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T
(232.13(b) of this chapter). (Amended by Sec Act Rel No. 7122, Esch Act Rel
No. 35113, eff 1/30/95).
<PAGE>
March 23, 1998
Berenson & Company LLP
Certified Public Accounts and Consultants
135 West 50th Street
New York, NY 10020
212-977-6800
FAX: 212-245-3808 or 212-245-7098
http://www.berenson.com
email: [email protected]
1912 Sunderland Place, NW
Washington, DC 20036
202-331-1044
FAX: 202-331-1085
United States Security and
Exchange Commission
Washington, D.C. 20549
Re: Igene Biotechnology, Inc.
EIN: 52-1230461
To Whom It May Concern:
We are the independent auditors for Igene Biotechnology, Inc. We are unable at
this point in time to express an opinion on the Companys December 31, 1997
financial statements or review the 10-KSB as Igene is awaiting the outcome of
a significant subsequent event which could both impact the financial statement
disclosures and the Companys ability to continue as a going concern.
Respectfully yours,
/s/ Berenson & Company LLP
